0001209191-22-026891.txt : 20220503
0001209191-22-026891.hdr.sgml : 20220503
20220503190441
ACCESSION NUMBER: 0001209191-22-026891
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220430
FILED AS OF DATE: 20220503
DATE AS OF CHANGE: 20220503
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Wolff Stefani
CENTRAL INDEX KEY: 0001751790
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39398
FILM NUMBER: 22889044
MAIL ADDRESS:
STREET 1: C/O PRINCIPIA BIOPHARMA INC.
STREET 2: 400 EAST JAMIE COURT, SUITE 302
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Nurix Therapeutics, Inc.
CENTRAL INDEX KEY: 0001549595
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 270838048
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1130
BUSINESS ADDRESS:
STREET 1: 1700 OWENS STREET, SUITE 205
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
BUSINESS PHONE: (415) 660-5320
MAIL ADDRESS:
STREET 1: 1700 OWENS STREET, SUITE 205
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
FORMER COMPANY:
FORMER CONFORMED NAME: Nurix, Inc.
DATE OF NAME CHANGE: 20120509
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-04-30
0
0001549595
Nurix Therapeutics, Inc.
NRIX
0001751790
Wolff Stefani
C/O NURIX THERAPEUTICS, INC.
1700 OWENS STREET, SUITE 205
SAN FRANCISCO
CA
94158
0
1
0
0
EVP and COO
Common Stock
2022-04-30
4
M
0
962
0.00
A
962
D
Common Stock
2022-05-02
4
S
0
330
11.75
D
632
D
Restricted Stock Units
0.00
2022-04-30
4
M
0
962
0.00
D
Common Stock
962
14430
D
The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
Each RSU represents a contingent right to receive one share of the Issuer's common stock.
The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting.
RSUs do not expire; they either vest or are canceled prior to the vest date.
/s/ Christine Ring, as Attorney-in-Fact for Stefani Wolff
2022-05-03